1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1610
  5. Art Unit 1618
  6. Examiner Rogers

Examiner Rogers James W

1618-ROGERS-JAMES-W

Employment Information

Art Unit:1618 — Drug, bio-affecting and body treating compositions
Group:1610 — Pharmaceutical and Agricultural Compositions; Plant Growth Regulating Compositions: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs; In vivo Diagnostic Agents
Classes: 424 — Drug, bio-affecting and body treating compositions
514 — Drug, bio-affecting and body treating compositions
534 — Organic compounds -- part of the class 532-570 series
606 — Surgery
206 — Special receptacle or package
623 — Prosthesis (i.e., artificial body members), parts thereof, or aids and accessories therefor
436 — Chemistry: analytical and immunological testing
604 — Surgery
506 — Combinatorial chemistry technology: method, library, apparatus
600 — Surgery
Phone:(571) 272-7838
Email:james.rogers@uspto.gov
Location:VA 22314
Title:Pat Examnr Gen Chem
Service:20 years
Grade:GS-14

Grant Rate and Difficulty Ranking

79
3-Year Grant rate: 52% over 319 cases
Difficulty: Harder
Difficulty Percentile: 79th

With Examiner Rogers, you have a 52% chance of getting an issued patent by 3 years after the first office action. Examiner Rogers is a harder examiner and in the 79th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Rogers, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1618

Examiner Rogers's grant rate is higher than that of Art Unit 1618 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Rogers 1.9
Art Unit 1618 2.0

Interview Benefit

Grant Rate without Interview

Examiner Rogers has granted 131 of 255 cases without any applicant-requested interviews for a grant rate of 51%.

Grant Rate with Interview

Examiner Rogers has granted 35 of 64 cases with at least one applicant-requested interview for a grant rate of 55%.

Interview Benefit

With Examiner Rogers, conducting an interview increases your chance of getting a patent granted by 8%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17280760 Degradable Hyaluronic Acid Hydrogels Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18202377 Dressings Comprising Platelet Lysate Patented View
17286123 Chemiluminescent And Fluorescent Nanoparticle For Optical Imaging Of Cancer Patented View
17640259 Manganese Chelate Isomers Abandoned View
19324663 Marine Organism Infused Effervescent Tablet For Producing Enhanced Suspensions Patented View
18152430 Biocompatible Hydrogel Treatments For Retinal Detachment Abandoned View
16343732 Simvastatin And Chemotherapeutic Conjugates With A Heptamethine Carbocyanine Dye Resensitize Human Tumors To Hormonal Antagonists And Chemotherapy Abandoned View
18498744 Nitrogen-Containing Macrocyclic Conjugates As Radiopharmaceuticals Patented View
17587595 Treatment Approach By Targeted Delivery Of Bioactive Molecules Patented View
15526383 Surgical Articles And Methods For Detection Abandoned View
18588605 Compositions And Methods Of Use Thereof Patented View
17790079 Multimodal Fluorine-Cy3/5/7-Dota-Hapten Compositions, Diagnostics, Fluorescence Guided Surgery And Radioimmunotherapy Patented View
17150310 Imageable Polymers Abandoned View
17198006 Novel Block Copolymer And Micelle Compositions And Methods Of Use Thereof Patented View
17368574 Photodynamic Therapy Composition Patented View
17431396 Prostate Specific Membrane Antigen (Psma) Ligands With Improved Tissue Specificity Abandoned View
16973329 Novel Compounds For Diagnosis Abandoned View
17774529 Cross-Linking Compounds And Methods Of Use Thereof Patented View
17283412 Bio-Inspired Degradable Tough Adhesives For Diverse Wet Surfaces Abandoned View
17425857 Delivery Of Macromolecules Into The Central Nervous System Via The Bloodstream Abandoned View
17279508 Tertiary Amino Lipidated Cationic Peptides For Nucleic Acid Delivery Abandoned View
17996420 Sterically Shielded Heptamethine Cyanine Dyes Patented View
17501608 Atherosclerosis Imaging Agents And Methods Of Using The Same Abandoned View
18902113 Polymer Nanoparticle Compositions For In Vivo Expression Of Polypeptides Patented View
17755429 Sodium-Dependent Glucose Transporter 2 As A Diagnostic And Therapeutic Target For Pre-Malignant Lesions Abandoned View
17085223 Nanostructure Enhanced Targeting (Nset) Of Inflammatory Cells Abandoned View
17722491 Azetidinyl-Acetamides As Cxcr7 Inhibitors Patented View
17579967 C60 Glutathione Dopa And Methods Abandoned View
17773282 Direct Fluorescent Glycan Labeling Abandoned View
17725237 Drug Combination Treatments Using Bone-Targeting Therapeutics For Bone And Bone-Related Disease Abandoned View
17415649 Dual Mode 18f-Labelled Theranostic Compounds And Uses Thereof Patented View
16090371 Iodinated Phenolic Lipids And Methods And Cosolvent Systems For Iodination Of Phenolic Lipids Patented View
17040809 Biodegradable Block Copolymer Patented View
17674512 Nootropic Fullerenes And Use Abandoned View
17257225 Compounds And Compositions For Treating Conditions Associated With Sting Activity Abandoned View
18516167 Nanoparticle Compositions Containing Sugar Functionalized Nucleic Acid Carriers Patented View
18529587 Virucidal Nanoparticles And Use Thereof Against Influenza Virus Patented View
17202063 Formulation For Soft Anticholinergic Analogs Patented View
16536093 Absorbable Copolymers With Improved Thermal Stability Patented View
18637431 Nanoparticles With Non-Covalently Bound Targeting Moieties For Use In A Therapeutic Method And For Non-Medical Use Abandoned View
17794807 Novel Gadolinium-Based Compound, Preparation Method Therefor, And Mri Contrast Agent Containing Same Patented View
17784215 Cgrp Antigonists Useful As Tracer Compounds For Positron Emission Tomography Abandoned View
18871962 1,4-Bis-(2-Hydroxy-Benzyl)-1,4,7-Triazacyclononane Derivatives And Similar Compounds As Ligands In Iron(Iii) Complexes For Use As Mri Contrast Agents Patented View
17208676 Formulation For Soft Anticholinergic Analogs Patented View
16802476 Azacyanine Dyes And Use Thereof Patented View
18351291 Conjugates Enhancing Total Cellular Accumulation Patented View
18643088 Stable Intravenous Diltiazem Hydrochloride Formulation And Use Thereof Patented View
18530764 Novel, Heavy Vitamin B12 Derivatives Patented View
17476852 Pyrimidine Nucleoside Compounds For Fluorescence Imaging And Spectroscopy Patented View
18595720 Gel Material For Ophthalmic Treatment Use Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.